LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC

Non-small cell lung carcinoma (NSCLC) patients who initially received tyrosine kinase inhibitor (TKI) therapy often acquired resistance via multiple complex mechanisms. The amplification of FGF3/4/19/CCND1 on chromosome 11q13 was found in many cancers with TKI resistance. However, the role of these...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Dongcheng, Liu, Hongguang, Gan, Jiadi, Zeng, Shinuan, Zhong, Fuhua, Zhang, Bin, Zhang, Zhe, Zhang, Siyu, Jiang, Lu, Wang, Guangsuo, Chen, Yixin, Kong, Feng-Ming Spring, Fang, Wenfeng, Wang, Lingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260114/
https://www.ncbi.nlm.nih.gov/pubmed/35814257
http://dx.doi.org/10.3389/fphar.2022.918317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260114/
https://www.ncbi.nlm.nih.gov/pubmed/35814257
http://dx.doi.org/10.3389/fphar.2022.918317

Ejemplares similares